Phase 3 Clinical Trials With Primary Completion Dates in September 2016

This is a list of Phase 3 trials with primary completion dates in September 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACOR Acorda Therapeutics, Inc. 2016-09-01 Phase 3 NCT02271217 A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke
ACRS Aclaris Therapeutics, Inc. 2016-09-01 Phase 3 NCT02667288 An Open-Label Safety Study of A-101 Solution
ACRS Aclaris Therapeutics, Inc. 2016-09-01 Phase 3 NCT02667275 A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
ACRS Aclaris Therapeutics, Inc. 2016-09-01 Phase 3 NCT02667236 A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
ARRY Array BioPharma Inc. 2016-09-01 Phase 3 NCT01909453 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
EARS Auris Medical Holding AG 2016-09-01 Phase 3 NCT02040194 AM-101 in the Treatment of Acute Tinnitus 3
FOLD Amicus Therapeutics, Inc. 2016-09-01 Phase 3 NCT02384460 ESSENCE Study: Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
INNL Innocoll Holdings 2016-09-01 Phase 3 NCT02447172 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
JAZZ Jazz Pharmaceuticals plc 2016-09-01 Phase 3 NCT02348606 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
JAZZ Jazz Pharmaceuticals plc 2016-09-01 Phase 3 NCT02348593 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
LXRX Lexicon Pharmaceuticals, Inc. 2016-09-01 Phase 3 NCT02421510 Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
LXRX Lexicon Pharmaceuticals, Inc. 2016-09-01 Phase 3 NCT02384941 Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
MYGN Myriad Genetics, Inc. 2016-09-01 Phase 3 NCT01874353 Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NWBO Northwest Biotherapeutics, Inc. 2016-09-01 Phase 3 NCT00045968 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
OCUL Ocular Therapeutix, Inc. 2016-09-01 Phase 3 NCT02736175 Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
RIGL Rigel Pharmaceuticals, Inc. 2016-09-01 Phase 3 NCT02076412 A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
RMD ResMed Inc. 2016-09-01 Phase 3 NCT01335087 Continuous Positive Airway Pressure (CPAP) in Patients With Acute Coronary Syndrome and Obstructive Sleep Apnea (OSA)
TARO Taro Pharmaceutical Industries Ltd. 2016-09-01 Phase 3 NCT02595073 Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis